CreatorsPublishersAdvertisers

#Emergent Biosolutions

modernreaders.com

Palisade Capital Management LLC NJ Has $37.95 Million Stake in Emergent BioSolutions Inc. (NYSE:EBS)

Palisade Capital Management LLC NJ decreased its position in Emergent BioSolutions Inc. (NYSE:EBS) by 3.8% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 602,480 shares of the biopharmaceutical company’s stock after selling 23,489 shares during the period. Emergent BioSolutions makes up 0.9% of Palisade Capital Management LLC NJ’s holdings, making the stock its 25th biggest holding. Palisade Capital Management LLC NJ owned about 1.12% of Emergent BioSolutions worth $37,950,000 at the end of the most recent quarter.
STOCKS
Picture for Palisade Capital Management LLC NJ Has $37.95 Million Stake in Emergent BioSolutions Inc. (NYSE:EBS)
theusexpressnews.com

What is happening with Emergent Biosolutions Stock?

The share price of Emerging Biosolutions, a specialized biopharmaceutical company, has fallen by 15% over the last twenty-one trading days, while it is down 42% since the start of the year. The EBS stockpile has had a rough year so far, with its manufacturing facility in Baltimore facing heat after a batch of Johnson & Johnson Covid-19 vaccine was contaminated. The US FDA inspected the manufacturing facility and made nine observations. It was April and the company went out of its way to address all concerns. Towards the end of July, the US FDA approved the reopening of the Baltimore plant and since then the regulator has cleared several lots of Johnson & Johnson’s Covid-19 vaccine from that facility. Emergent also recently signed an agreement with Canada-based Providence Therapeutics to manufacture its mRNA-based Covid-19 vaccine candidate.
MEDICAL & BIOTECH
Picture for What is happening with Emergent Biosolutions Stock?

FDA Coronavirus Update: September 17

The U.S. Food and Drug Administration announced the following actions taken in its ongoing response effort to the COVID-19 pandemic:. On Sept. 17, the FDA issued a Letter to Health Care Providers to alert clinical laboratory staff and health care providers about the potential for false-positive results with Abbott Alinity m SARS-CoV-2 AMP and Alinity m Resp-4-Plex AMP Kits. The Letter to Health Care Providers includes important information about Abbott Alinity m SARS-CoV-2 AMP and Alinity m Resp-4-Plex AMP Kits, including details on potential false-positive results, recommendations for clinical laboratory staff and health care providers, actions the FDA is taking, and instructions for reporting problems with the Alinity m SARS-CoV-2 AMP or Alinity m Resp-4-Plex AMP Kits.
PUBLIC HEALTH
Picture for FDA Coronavirus Update: September 17
TRENDING TOPICS
modernreaders.com

Emergent BioSolutions (NYSE:EBS) Hits New 12-Month Low at $54.87

Emergent BioSolutions Inc. (NYSE:EBS)’s share price reached a new 52-week low during trading on Tuesday . The stock traded as low as $54.87 and last traded at $54.87, with a volume of 2787 shares traded. The stock had previously closed at $56.36. Several equities analysts have commented on EBS shares....
STOCKS
homelandprepnews.com

Emergent BioSolutions, Providence Therapeutics sign development, manufacturing agreement for COVID-19 vaccine

Gaithersburg, Md.-based Emergent BioSolutions Inc. and Canadian vaccine company Providence Therapeutics said on Tuesday they have entered into a $90 million, five-year development and manufacturing agreement to support Providence’s COVID-19 messenger RNA (mRNA) vaccine candidate. Already collaborators since February, the agreement expands the partnership between the two companies by guaranteeing...
MEDICAL & BIOTECH

Emergent to make Providence Therapeutics' potential COVID-19 vaccine

Sept 14 (Reuters) - Emergent BioSolutions Inc (EBS.N) signed a five-year agreement with Providence Therapeutics to develop and manufacture its COVID-19 vaccine candidate, the companies said on Tuesday. The agreement signed between Emergent and Providence Therapeutics is valued at about $90 million. Our Standards: The Thomson Reuters Trust Principles.
MEDICAL & BIOTECH
contractpharma.com

Emergent BioSolutions, Providence Therapeutics Enter Vaccine Manufacturing Partnership

Ink multi-year development and manufacturing agreement for mRNA COVID-19 vaccine candidate, PTX-COVID19-B. Emergent BioSolutions and Providence Therapeutics have entered into a five-year contract development and manufacturing (CDMO) services agreement spanning Emergent’s integrated capabilities, including development services, bulk drug substance formulation and drug product manufacturing, to support Providence’s COVID-19 messenger RNA (mRNA) vaccine development. In 2022, Emergent will manufacture tens of millions of doses of PTX-COVID19-B drug product, as well as batches of PTX-COVID19-B formulated bulk drug substance with the potential to yield hundreds of millions more doses, for global populations in need of pandemic relief.
PROVIDENCE, RI
com-unik.info

Emergent BioSolutions Inc. (NYSE:EBS) Shares Sold by Victory Capital Management Inc.

Victory Capital Management Inc. reduced its stake in Emergent BioSolutions Inc. (NYSE:EBS) by 55.2% in the 2nd quarter, Holdings Channel reports. The firm owned 20,181 shares of the biopharmaceutical company’s stock after selling 24,910 shares during the quarter. Victory Capital Management Inc.’s holdings in Emergent BioSolutions were worth $1,272,000 as of its most recent SEC filing.
STOCKS
firstwordpharma.com

Emergent BioSolutions Secures Multi-Year Development and Manufacturing Agreement with Providence Therapeutics for Its mRNA COVID-19 Vaccine Candidate, PTX-COVID19-B

Total baseline value for Emergent is approximately $90 million USD, further expanding the collaboration between the companies, which began in February 2021. GAITHERSBURG, Md. and CALGARY, AB, Sept. 14, 2021 /CNW/ - Emergent BioSolutions Inc. (NYSE: EBS) and Providence Therapeutics today announced they have entered into a five-year contract development and manufacturing (CDMO) services agreement spanning Emergent's integrated capabilities, including development services, bulk drug substance formulation and drug product manufacturing, to support Providence's COVID-19 messenger RNA (mRNA) vaccine development. In 2022, Emergent will manufacture tens of millions of doses of PTX-COVID19-B drug product, as well as batches of PTX-COVID19-B formulated bulk drug substance with the potential to yield hundreds of millions more doses, for global populations in need of pandemic relief.
MEDICAL & BIOTECH
modernreaders.com

Russell Investments Group Ltd. Boosts Position in Emergent BioSolutions Inc. (NYSE:EBS)

Russell Investments Group Ltd. lifted its stake in shares of Emergent BioSolutions Inc. (NYSE:EBS) by 210.4% during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 78,623 shares of the biopharmaceutical company’s stock after acquiring an additional 53,295 shares during the period. Russell Investments Group Ltd. owned 0.15% of Emergent BioSolutions worth $4,956,000 as of its most recent filing with the Securities & Exchange Commission.
STOCKS
modernreaders.com

Mutual of America Capital Management LLC Sells 25,500 Shares of Emergent BioSolutions Inc. (NYSE:EBS)

Mutual of America Capital Management LLC decreased its holdings in Emergent BioSolutions Inc. (NYSE:EBS) by 25.8% in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 73,245 shares of the biopharmaceutical company’s stock after selling 25,500 shares during the quarter. Mutual of America Capital Management LLC’s holdings in Emergent BioSolutions were worth $4,614,000 as of its most recent SEC filing.
STOCKS
YOU MAY ALSO LIKE